en · de · es · fr · pt
cjc-1295-notes.peptides1004.com › News › Mechanism And Pharmacokinetics — Evidence Review

Mechanism And Pharmacokinetics — Evidence Review

By Editorial Desk · published 2025-08-09 · last reviewed 2025-09-02 · News

If you have been reading about DAC linker and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-09-02. Numbers and descriptions here follow the published literature rather than marketing material.

Mechanism and Pharmacokinetics

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

Albumin Binding and Duration of Action

Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.

Cjc-1295 at a glance

PropertyValueNotes
Target receptorGHRH receptor (GHRHR)Expressed on pituitary somatotrophs
Primary actionStimulates growth hormone releaseAmplifies pulse size
Half-life, albumin-binding formSeveral days as reportedSlow release from albumin complex
Half-life, unmodified analogAbout 30 minutes in animal estimatesCleared by proteases and filtration
Common analytical approachLC-MS/MS for peptide, immunoassay for hormonesMethods answer different questions

CJC-1295 Structure And Mechanism

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

Related pages on this site

Background and Molecular Design

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Structure And Receptor Pharmacology

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Further detail

== Adverse effects == A 2010 Cochrane review of finasteride for BPH found that, in men with a weighted mean age of 62.4, adverse effects are rare in men with already enlarged prostates; "nevertheless, men taking finasteride are at increased risk for impotence, erectile dysfunction, decreased libido, and ejaculation disorder, versus placebo." As of 2016, fresh evidence suggested such effects, along with disturbed neurosteroid production, may persist after finasteride use is stopped. Finasteride is contraindicated in pregnancy. The US Food and Drug Administration (FDA) advises that donation of blood or plasma be deferred for at least one month after taking the last dose of finasteride. The FDA has added a warning to 5α-reductase inhibitors concerning an increased risk of high-grade prostate cancer, as the treatment of BPH lowers PSA (prostate-specific antigen), which could mask the development of prostate cancer. Although overall incidence of male breast cancer in clinical trials for finasteride 5 mg was not increased, there are post-marketing reports of breast cancer in association with its use, though available evidence does not provide clarity as to whether there is a causative relationship between finasteride and these cancers. A 2018 meta-analysis found no higher risk of breast cancer with 5α-reductase inhibitors. Some men develop gynecomastia (breast development or enlargement) following finasteride usage. The risk of gynecomastia with 5α-reductase inhibitors is low at about 1.5%. Depressive symptoms and suicidality have been reported.

Besides being a physical barrier, the sulcular epithelium is able to release antimicrobial peptides which retard the growth of bacteria.This is through the secretion of defensins (β-defensins (hBD-1 and hBD-2)) which are a unique feature of the sulcular epithelium as compared to the junctional epithelium. However if plaque build-up occurs due to the lack of proper oral hygiene practices, bacteria are able to adhere to the sulcular epithelium using their fimbriae. It is discovered that the biofilm adhered to the sulcular epithelium consists of a rich content of glycocalyces, suggesting that these virulence factors allow the survival and colonisation of the periodontal pathogens. The fimbriae then induces the inflammatory response via the release of proinflammatory cytokines, leading to bone resorption. During periodontal disease, the epithelial barrier of the sulcular epithelium becomes discontinuous or ulcerated, compromising the integrity of these junctional complexes. This results in an increase in epithelial permeability and facilitates the passage of bacterial products. This is further promoted through the non-keratinised nature of the epithelium which also acts as a semi-permeable membrane. The transport of harmful bacterial products into the gingiva allows the detection of bacteria action which allows the sulcular epithelium to retaliate through the diffusion of the gingival crevicular fluid (GCF) containing inflammatory cells (neutrophils & small lymphocytes) & inflammatory mediators (IL-8, CXCL8 chemokines) into the sulcus.

=== Formation of one bond === The (1,5) or (3,4) bond can be formed by the reaction of an imidate and an α-aminoaldehyde or α-aminoacetal. The example below applies to imidazole when R1 = R2 = hydrogen.

Theodore Ryder (September 14, 1916 – March 8, 1993), often called Ted or Teddy Ryder, was, at the age of five, one of the first twelve people with diabetes in the world to be treated using insulin. When he died in 1993 at the age of 76, he became the world's first person to live 70 years with diabetes and probably the longest documented case of sustained insulin treatment in medical history. He was also the last survivor of the first twelve diabetes patients treated with insulin.

Sources: en.wikipedia.org

Supporting material

=== Senses === Cephalopods have advanced vision, can detect gravity with statocysts, and have a variety of chemical sense organs. Octopuses use their arms to explore their environment and can use them for depth perception.

=== Calreticulin === Calreticulin – especially its lectin-like domain – interacts with MHC-I. The P domain faces the MHC-I peptide-binding site towards ERp57. This orientation makes it possible for tapasin to attach and secure MHC-I. This translocation of TAP facilitates its opening out into an ER luminal cavity, edged by standard membrane entry points such as those for tapasin and MHC-I. These two entry points facilitate the recruitment of MHC-I with optimal peptide loading and eventual release of MHC-I in T-cell surfaces for recognition.

Acrodynia (calomel disease, erythredemic polyneuropathy, pink disease) Acute generalized exanthematous pustulosis (pustular drug eruption, toxic pustuloderma) Adverse reaction to biologic agents Adverse reaction to cytokines Allopurinol hypersensitivity syndrome Anticoagulant-induced skin necrosis Anticonvulsant hypersensitivity syndrome Bromoderma Bullous drug reaction (bullous drug eruption, generalized bullous fixed drug eruption, multilocular bullous fixed drug eruption) Chemotherapy-induced acral erythema (palmoplantar erythrodysesthesia syndrome) Chemotherapy-induced hyperpigmentation Drug-induced acne Drug-induced angioedema Drug-related gingival hyperplasia Drug-induced lichenoid reaction (drug-induced lichen planus, lichenoid drug eruption) Drug-induced lupus erythematosus Drug-induced nail changes Drug-induced pigmentation Drug-induced urticaria Drug reaction with eosinophilia and systemic symptoms Erythema multiforme major (erythema multiforme minor–erythema multiforme von Hebra) Exudative hyponychial dermatitis Fixed drug reaction Halogenoderma Heparin necrosis HIV disease-related drug reaction Hydroxyurea dermopathy Injection site reaction Iododerma Leukotriene receptor antagonist-associated Churg–Strauss syndrome Linear IgA bullous dermatosis (linear IgA dermatosis) Photosensitive drug reaction Red man syndrome Severe cutaneous adverse reactions (includes DRESS syndrome, Steven Johnson syndrome, Toxic epidermal necrolysis, Stevens-Johnson/toxic epidermal necrolysis overlap syndrome, and Acute generalized exanthematous pustulosis) Scleroderma-like reaction to taxanes Serum sickness-like reaction Steroid acne Steroid folliculitis Stevens–Johnson syndrome Sulfonamide hypersensitivity syndrome Texier's disease Toxic epidermal necrolysis (Lyell's syndrome) Urticarial erythema multiforme Vitamin K reaction Warfarin necrosis

== Lexicology == The Latin term impotentia coeundi describes simple inability to insert the penis into the vagina; it is now mostly replaced by more precise terms, such as erectile dysfunction (ED). The study of ED within medicine is covered by andrology, a sub-field within urology. Research indicates that ED is common, and it is suggested that approximately 40% of males experience symptoms compatible with ED, at least occasionally. The condition is also on occasion called phallic impotence. Its antonym, or opposite condition, is priapism.

=== Melting point === As a pure material, bronopol has a melting point of about 130 °C. However, due to its polymorphic characteristics, bronopol undergoes a lattice rearrangement at 100 to 105 °C and this can often be wrongly interpreted as the melting point. At temperatures above 140 °C, bronopol decomposes exothermically releasing hydrogen bromide and oxides of nitrogen.

Sources: en.wikipedia.org

Supporting material

=== Acute wounds === An acute wound is any wound which results from direct trauma and progresses through the four stages of wound healing along an expected timeline. The first stage, hemostasis, lasts from minutes to hours after initial injury. This stage is followed by the inflammatory phase which typically lasts 1 to 3 days. Proliferation is the third stage of wound healing and lasts from a few days up to a month. The fourth and final phase of wound healing, remodeling/scar formation, typically lasts 12 months but can continue as long as 2 years after the initial injury. Acute wounds can further be classified as either open or closed. An open wound is any injury whereby the integrity of the skin has been disrupted and the underlying tissue is exposed. A closed wound, on the other hand, is any injury in which underlying tissue has been damaged but the overlying skin is still intact.

587,000 m² of built-up industrial and logistics space, with 93,000 m² dedicated to cold storage. 250,000 m² of warehousing capacity under development with AED 621 million investment. Serviced plots, cold storage units, light industrial units, and startup-ready facilities.

==== II. Nanoparticle and Liposome Attachment ==== Attachment of liposomes or nanoparticles to the exterior of the lipid microbubble has also been explored to increase microbubble payload. Upon microbubble destruction with ultrasound, these smaller particles can extravasate into the tumor tissue. Furthermore, through attachment of these particles to microbubbles as opposed to co-injection, the drug is confined to the blood stream instead of accumulating in healthy tissues, and the treatment is relegated to the location of ultrasound therapy. This microbubble modification is particularly attractive for Doxil, a lipid formulation of Doxorubicin already in clinical use. An analysis of nanoparticle infiltration due to microbubble destruction indicates that higher pressures are necessary for vascular permeability and likely improves treatment by promoting local fluid movement and enhancing endocytosis.

=== Risk factors === Heavy lifting, obesity, sedentary lifestyle and lack of exercise can increase the risk of back pain. Cigarette smokers are more likely to experience back pain than are nonsmokers. Excessive weight gain in pregnancy is also a risk factor for back pain. In general, fatigue can worsen pain. A few studies suggest that psychosocial factors such as work-related stress, burnout, sleep problems, and dysfunctional family relationships may correlate more closely with back pain than do structural abnormalities revealed in X-rays and other medical imaging scans. Back pain physical effects can range from muscle aching to a shooting, burning, or stabbing sensation. Pain can radiate down the legs and can be increased by bending, twisting, lifting, standing, or walking. While the physical effects of back pain are always at the forefront, back pain also can have psychological effects. Back pain has been linked to depression, anxiety, stress, and avoidance behaviors due to mentally not being able to cope with the physical pain. Both acute and chronic back pain can be associated with psychological distress in the form of anxiety (worries, stress) or depression (sadness, discouragement). Psychological distress is a common reaction to the suffering aspects of acute back pain, even when symptoms are short-term and not medically serious.

Sources: en.wikipedia.org

Frequently asked questions

How long does the albumin-binding form remain active?

Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.

What do researchers measure after administering the peptide?

Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.

Are the clinical effects well established?

Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.

How does the reactive group attach to albumin?

A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.

Network